Home Interviews BioStock Investor Pitch: Alligator Bioscience

BioStock Investor Pitch: Alligator Bioscience

Soren Bregenholt, CEO Alligator Bioscience

BioStock Investor Pitch: Alligator Bioscience

4 May, 2023

Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for the treatment of solid tumours in a collaboration with Aptevo Therapeutics. Now the company is carrying out a rights issue of approximately 199 million SEK. Alligator’s CEO Søren Bregenholt tells us more about ongoing activities in a BioStock Investor Pitch today at 09.15 am. 

See Alligator Bioscience CEO Søren Bregenholt present the company below.

YouTube video

This material has been prepared for marketing purposes and is not and should not be considered a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and more information about the company have been presented in the EU Growth Prospectus published at alligatorbioscience.se on 26 April 2023. The EU Growth Prospectus has been approved and registered by the Financial Supervisory Authority. The marketing material is not intended to replace the EU growth prospectus as a basis for decisions to subscribe to shares in Alligator Bioscience and does not constitute a recommendation to subscribe to shares in Alligator Bioscience. Investors intending or considering investing in Alligator Bioscience are therefore advised to read the EU growth prospectus.

Artikelns innehåll är sponsrat av det aktuella bolaget som förekommer i texten. BioStock tillhandahåller inte investeringsrådgivning, förmedlar inga investeringsorder och tar inget ansvar för agerande och/eller eventuell förlust eller skada av något slag som grundar sig på användandet av innehåll som publicerats på BioStock.se. Varje investeringsbeslut fattas istället självständigt av den enskilde investeraren.

Prenumerera på BioStocks nyhetsbrev